Does Rivaroxaban Better than Vitamin K Antagonists in Atrial Fibrillation Patients Undergoing PCI?
Open Access
- 30 December 2016
- journal article
- Published by Peertechz Publications Private Limited in Archives of Hematology Case Reports and Reviews
- Vol. 1 (1), 005-006
- https://doi.org/10.17352/ahcrr.000003
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCIThe New England Journal of Medicine, 2016
- 2014 ESC/EACTS Guidelines on myocardial revascularizationEuropean Heart Journal, 2014
- The optimal management of patients on oral anticoagulation undergoing coronary artery stentingThrombosis and Haemostasis, 2014
- Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) TrialCirculation, 2013
- Correction to Dosage in: Primary and Secondary Prevention of Cardiovascular Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2012
- Risk of Bleeding With Single, Dual, or Triple Therapy With Warfarin, Aspirin, and Clopidogrel in Patients With Atrial FibrillationJAMA Internal Medicine, 2010
- Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation: Implications for Bleeding Risk and PrognosisJournal of the American College of Cardiology, 2008